earnings
confidence high
sentiment positive
materiality 0.80
Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M
Adaptive Biotechnologies Corp
2025-FY EPS reported
-$0.39
revenue$276,976,000
- Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.
- MRD segment achieved positive Adjusted EBITDA and cash flow; MRD revenue Q4 $61.9M (+54%), FY $212.3M (+46%).
- clonoSEQ test volume Q4 30,038 (+43% YoY); FY 105,587 (+39% YoY); expanded Medicare coverage in mantle cell lymphoma.
- Signed two non-exclusive immune receptor data licensing agreements with Pfizer.
- FY2026 guidance: MRD revenue $255-265M; total OpEx $350-360M; management expects company-wide profitability in 2026.